ArticleMolecular biology reports2026
Peripheral blood mRNA expression of IL37, IL1F10, and C17orf99 genes is altered in patients with B-acute lymphoblastic leukemia: a case-control study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute lymphoblastic leukemia (ALL) is a hematological malignancy of two main types, B-ALL and T-ALL, with B-ALL being the most common. Growing evidence suggests that B-ALL pathophysiology is linked to immune system dysfunction in which cytokines play a pivotal role. Interleukin (IL)-37, IL-38, and IL-40, encoded by IL37, IL1F10, and C17orf99 genes, respectively, are novel cytokines involved in regulating immune functions and are proposed to influence cancer pathogenesis. However, these cytokines have not been studied in B-ALL, either genetically or phenotypically. Therefore, this research aimed to evaluate gene expression of IL37, IL1F10, and C17orf99 to explore their association with B-ALL.
methodsA case-control study was conducted on 114 B-ALL patients and 100 controls. A quantitative analysis based on real-time PCR was performed to measure IL37, IL1F10, and C17orf99 mRNA expression levels in peripheral blood.
resultsIL37 (probability < 0.001) and C17orf99 (probability < 0.001) expression levels were significantly lower, while IL1F10 expression levels (probability < 0.001) were significantly higher in B-ALL patients compared to controls. Multiple binary logistic regression analysis demonstrated that mRNA expression of these genes was significantly associated with B-ALL. However, the estimated area under the curve (AUC) indicated that the discriminatory performance (B-ALL versus controls) was fair for IL37 (AUC = 0.77), poor for IL1F10 (AUC = 0.69), and considerable for C17orf99 (AUC = 0.82).
conclusionsIL37 and C17orf99 genes showed downregulated expression, while IL1F10 gene showed upregulated expression in B-ALL. Dysregulated expression of these genes was associated with B-ALL and may be of significance in disease identification. However, further research is warranted to understand these molecular vulnerabilities in B-ALL.
Indexed as
Identifiers
42268443What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.